Novozymes remains confident in bioenergy despite low growth

With a new strategy in hand, Novozymes is ready turn its back on years of repeated disappointment. Bioenergy will still play a crucial role, though no major growth is expected. "It's one of the things we invest a lot in," says EVP.

Photo: Bidstrup Stine/Ritzau Scanpix

During Novozymes' virtual capital markets day held Tuesday afternoon, the company's chief executive said that it's not merely an enzyme producer, but much more than that.

According to CEO Ester Baiget, it's only logical to equate Novozymes with enzyme production. But the company doesn't see itself in that way. This is evident in a new strategy meant to boost the company ahead of 2025 and, not least, lay to rest the past six years, which have not at all lived up to the company's expectations – an aspect also highlighted by Baiget.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from EnergyWatch

Welcon's record revenue shaves paper-thin profit margin

State-subsidized steel from China is making the Danish wind turbine tower supplier's profit bottom out. If the EU doesn't decide to impose a tariff on Chinese steel this year, Welcon predicts that several suppliers will collapse. "But it won't be us," the CEO says.

Further reading

Related articles

Trial banner

Latest News

See all jobs